PMID- 9924191
OWN - NLM
STAT- MEDLINE
DCOM- 19990421
LR  - 20190709
IS  - 0022-0795 (Print)
IS  - 0022-0795 (Linking)
VI  - 160
IP  - 2
DP  - 1999 Feb
TI  - Vitamin D analogue EB1089-induced prostate regression is associated with 
      increased gene expression of insulin-like growth factor binding proteins.
PG  - 223-9
AB  - Vitamin D analogues have an antiproliferative effect on prostate cancer cells in 
      vitro and thus have been proposed as candidates for chemoprevention of prostate 
      cancer. Insulin-like growth factor (IGF)-I has been shown to protect cells from 
      apoptosis and plays an essential role in normal prostate physiology. We have 
      studied the effects of the 1,25-dihydroxyvitamin D3 analogue EB1089 on the IGF 
      system in the prostate in vivo. Treatment of rats with EB1089 for 14 days caused 
      a 25% decrease in ventral prostate weight. Apoptosis was detected in prostate 
      sections of EB1089-treated rats by terminal deoxynucleotidyl transferase-mediated 
      dUTP nick end labeling(TUNEL) assay and histologic examination of 
      hematoxylin/eosin stained tissue sections indicated that secretory epithelial 
      cells were flattened, a characteristic of cells undergoing pressure-induced 
      atrophy. Ventral prostate regression was associated with 15- to 25-fold increases 
      in gene expression of IGF-binding proteins (IGFBPs)-2,-3,-4 and -5. We also 
      observed a 40-fold increase in prostatic IGF-I mRNA levels in response to EB1089. 
      Although we have previously shown that castration of rats leads to upregulation 
      of IGFBPs in the ventral prostate, EB1089 treatment had no effect on serum levels 
      of dihydrotestosterone or free testosterone. These results suggest that prostate 
      regression induced by EB1089 may be related to alterations in availability of 
      IGF-I as a result of increased production of IGFBPs.
FAU - Nickerson, T
AU  - Nickerson T
AD  - Lady Davis Institute for Medical Research, McGill University, 3755 Cote Ste 
      Catherine Road, Montreal, Quebec, Canada H3T 1E2.
FAU - Huynh, H
AU  - Huynh H
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Endocrinol
JT  - The Journal of endocrinology
JID - 0375363
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 2)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 4)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 5)
RN  - 0 (Insulin-Like Growth Factor Binding Proteins)
RN  - 0 (RNA, Messenger)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - FXC9231JVH (Calcitriol)
RN  - Q0OZ0D9223 (seocalcitol)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/drug effects
MH  - Blotting, Northern
MH  - Calcitriol/*analogs & derivatives/pharmacology
MH  - Gene Expression
MH  - Insulin-Like Growth Factor Binding Protein 2/genetics
MH  - Insulin-Like Growth Factor Binding Protein 3/genetics
MH  - Insulin-Like Growth Factor Binding Protein 4/genetics
MH  - Insulin-Like Growth Factor Binding Protein 5/genetics
MH  - Insulin-Like Growth Factor Binding Proteins/*genetics
MH  - Insulin-Like Growth Factor I/genetics
MH  - Male
MH  - Prostate/*drug effects/metabolism/physiology
MH  - RNA, Messenger/analysis
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1999/01/30 00:00
MHDA- 1999/01/30 00:01
CRDT- 1999/01/30 00:00
PHST- 1999/01/30 00:00 [pubmed]
PHST- 1999/01/30 00:01 [medline]
PHST- 1999/01/30 00:00 [entrez]
AID - 10.1677/joe.0.1600223 [doi]
PST - ppublish
SO  - J Endocrinol. 1999 Feb;160(2):223-9. doi: 10.1677/joe.0.1600223.